The effect of eligibility for antiretroviral therapy on body mass index and blood pressure in KwaZulu-Natal, South Africa.
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Retroviral Agents
/ therapeutic use
Blood Pressure
/ drug effects
Body Mass Index
Cross-Sectional Studies
Female
HIV Infections
/ drug therapy
Heart Disease Risk Factors
Humans
Male
Middle Aged
Patient Selection
Population Surveillance
Risk Factors
Rural Population
/ statistics & numerical data
Secondary Prevention
/ statistics & numerical data
South Africa
/ epidemiology
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 07 2021
19 07 2021
Historique:
received:
14
01
2021
accepted:
05
07
2021
entrez:
20
7
2021
pubmed:
21
7
2021
medline:
1
12
2021
Statut:
epublish
Résumé
We use a regression discontinuity design to estimate the causal effect of antiretroviral therapy (ART) eligibility according to national treatment guidelines of South Africa on two risk factors for cardiovascular disease, body mass index (BMI) and blood pressure. We combine survey data collected in 2010 in KwaZulu-Natal, South Africa, with clinical data on ART. We find that early ART eligibility significantly reduces systolic and diastolic blood pressure. We do not find any significant effects on BMI. The effect on blood pressure can be detected up to three years after becoming eligible for ART.
Identifiants
pubmed: 34282184
doi: 10.1038/s41598-021-94057-z
pii: 10.1038/s41598-021-94057-z
pmc: PMC8289961
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14718Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR003143
Pays : United States
Informations de copyright
© 2021. The Author(s).
Références
AIDS. 2004 Sep 3;18(13):1835-43
pubmed: 15316345
Drugs. 2013 May;73(7):651-72
pubmed: 23591907
Open Forum Infect Dis. 2016 Oct 8;3(4):ofw213
pubmed: 27942541
AIDS. 2005 Jun 10;19(9):953-60
pubmed: 15905677
AIDS. 2012 Jul 31;26 Suppl 1:S1-5
pubmed: 22713477
Circulation. 2018 Sep 11;138(11):1100-1112
pubmed: 29967196
Clin Infect Dis. 2020 Sep 12;71(6):1379-1389
pubmed: 31606734
Lancet HIV. 2015 Feb;2(2):e40-1
pubmed: 26424459
Neurol Res. 2017 Jun;39(6):573-580
pubmed: 28415916
AIDS. 2007 Mar 30;21(6):685-92
pubmed: 17413689
PLoS Med. 2013;10(4):e1001418
pubmed: 23585736
Lancet HIV. 2020 Apr;7(4):e279-e293
pubmed: 32243826
Lancet. 2016 Mar 5;387(10022):957-967
pubmed: 26724178
Epidemiology. 2014 Sep;25(5):729-37
pubmed: 25061922
PLoS One. 2013 May 28;8(5):e63623
pubmed: 23723990
Drugs. 2021 Feb;81(3):299-315
pubmed: 33400239
AIDS. 2012 Jul 31;26 Suppl 1:S19-30
pubmed: 22781175
Obesity (Silver Spring). 2017 Jan;25(1):200-206
pubmed: 27925407
J Am Heart Assoc. 2017 May 22;6(5):
pubmed: 28533305
BMC Infect Dis. 2015 Oct 26;15:452
pubmed: 26497054
J Am Soc Hypertens. 2017 Aug;11(8):530-540
pubmed: 28689734
AIDS. 2017 Apr 24;31(7):1017-1024
pubmed: 28252526
AIDS Rev. 2016 Oct-Dec;18(4):198-211
pubmed: 27438580
PLoS One. 2016 Aug 23;11(8):e0158264
pubmed: 27552195
Bull World Health Organ. 2010 Nov 1;88(11):847-53
pubmed: 21076566
J Clin Epidemiol. 2017 Sep;89:21-29
pubmed: 28365303
J Hum Hypertens. 2016 Jun;30(6):355-62
pubmed: 26446389
Int J Epidemiol. 2013 Dec;42(6):1754-71
pubmed: 24415610
HIV Med. 2012 Sep;13(8):453-68
pubmed: 22413967
J Clin Hypertens (Greenwich). 2013 Feb;15(2):101-6
pubmed: 23339727
J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):e79-86
pubmed: 21157360
Bull World Health Organ. 2010 Aug 1;88(8):593-600
pubmed: 20680124
PLoS One. 2018 Jul 30;13(7):e0201404
pubmed: 30059546
J Clin Hypertens (Greenwich). 2012 Oct;14(10):657-64
pubmed: 23031141
J Clin Epidemiol. 2017 Sep;89:53-66
pubmed: 28365306
AIDS. 2006 Apr 24;20(7):1019-26
pubmed: 16603854
Lancet HIV. 2017 May;4(5):e223-e230
pubmed: 28153470